HFD+CCl4-induced MASH Models

Obesity Models and Efficacy Services
60% HFD Induced Obesity (DIO) models45% HFHSD Induced Obesity(DIO) modelsC57BL/6-Alms1-delWild Mouse 750
Type II Diabetes Models and Efficacy Service
BKS-dbHFHSD+STZ Induced Diabetes Models
Liver Disease Models and Efficacy Services
CCl4-induced Liver Fibrosis ModelsHFD+CCl4-induced MASH ModelsBKS-db MASH ModelsB6-Alms1-del MASH ModelsOther MASH Models
Atherosclerosis Models and Efficacy Services
ApoE KO ModelsLdlr KO Models
Hyperlipidemia Models and Efficacy Services
hPCSK9-UTR ModelshPCSK9 Models
Gout/Hyperuricemia Models and Efficacy Services
Monosodium Urate (MSU)-induced Gouty Arthritis ModelsUrate Oxidase Knockout (Uox-KO) Gout Models

Study Outline

图片1.png

Figure 1. Overview of HFD+CCl4-induced MASH models.


Efficacy Data

图片2.png


Figure 2. Hepatic steatosis and fibrosis were observed in HFD+CCl4 group. Treatment with drug Int-747 (obecholic acid) and MGL-3196 significantly improved liver steatosis and fibrosis in MASH model. Data are presented as Mean±SD. *, P<0.05; ****, P<0.0001 by one way ANOVA with Tukey's post hoc test.


TALK WITH OUR EXPERTS

GemPharmatech is committed to protecting and respecting your privacy, and we'll only use your personal information to administer your account and to provide the products and services you requested from us. From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please click below to say how you would like us to contact you:

In order to provide you with the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please click the checkbox below.

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.